0000000000243842

AUTHOR

Dimitris Ziagkos

showing 2 related works from this author

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion

2018

The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46%…

MaleBLOODDatabases FactualIMPACTCHROMOSOMECancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]medicine.medical_treatment[SDV]Life Sciences [q-bio]MedizinHematopoietic stem cell transplantationPROGNOSTIC SCORING SYSTEMGastroenterology0302 clinical medicineRecurrencehemic and lymphatic diseasesMDSCumulative incidenceLENALIDOMIDEIncidenceIncidence (epidemiology)Hazard ratioHematopoietic Stem Cell TransplantationHematologyMiddle AgedAllograftsTP53 MUTATIONSEUROPEAN-SOCIETY3. Good healthSurvival Rate030220 oncology & carcinogenesisWORKING PARTYChromosomes Human Pair 5FemaleChromosome DeletionLife Sciences & BiomedicineDEL(5Q)del (5q)medicine.drugAdultmedicine.medical_specialtyImmunology3122 CancersDisease-Free SurvivalSettore MED/01 - Statistica Medica03 medical and health sciencesSex FactorsAll institutes and research themes of the Radboud University Medical CenterInternal medicinemedicineHumansMARROW-TRANSPLANTATIONSurvival rateLenalidomideTransplantationScience & Technologybusiness.industryMyelodysplastic syndromesmedicine.diseaseAllogeneic stem cell transplantationTransplantationMyelodysplastic Syndromesbusiness030215 immunology
researchProduct

Outcomes of Mismatched Related Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of the Chronic …

2016

Abstract Introduction: Allogeneic hematopoietic stem cell transplantation (HCT) is a treatment for CLL that can give long disease control. Even with the availability of kinase and BCL2 inhibitors, HCT is still performed in fit patients (pts) with high-risk CLL. Almost exclusively, outcomes on matched related and unrelated donor transplantations in CLL have been published. Recently, mismatched related donors are gaining interest because of the better outcome of haploidentical HCT with post-transplantation cyclophosphamide (PTCY). Methods: All pts with CLL who received a first allogeneic HCT with a mismatched related donor and whose data were available in the EBMT registry were analyzed. Medi…

medicine.medical_specialtybusiness.industryChronic lymphocytic leukemiaIncidence (epidemiology)medicine.medical_treatmentImmunologyRetrospective cohort studyContext (language use)Cell BiologyHematologyHematopoietic stem cell transplantationmedicine.diseaseBiochemistryTransplantationAutologous stem-cell transplantationInternal medicineCohortmedicinebusinessBlood
researchProduct